Communiqués Faron Pharmaceuticals Oy

Actions

FARN

FI4000153309

Recherche biotechnologique et médicale

Marché Fermé - London S.E. 17:35:22 04/09/2026			Varia. 5j.	Varia. 1 janv.
38,00 ^GBX	0,00%		-5,00%	-78,89%

27/08	Faron Pharmaceuticals annonce le recrutement du premier patient dans l'essai BEXAR initié par des investigateurs	CI
26/08	RÉSULTATS ET ACTIVITÉ : Empresaria relève ses prévisions grâce aux réductions de coûts	AN

Communiqués

04/09	FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY	PU
27/08	Faron Pharmaceuticals Oy : Announces First Patient Enrolled in BEXAR Investigator-Initiated Trial	PU
19/08	Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results	AQ
04/08	FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY	PU
03/08	Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds	PU
27/07	Inside Information: Faron Announces Encouraging First Overall Survival Data from Frontline Higher-Risk (HR) MDS Patients in the BEXMAB Phase 1/2 Trial	AQ
24/07	FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY	PU
13/07	Faron Pharmaceuticals Oy : Provides Update on Investigator-Initiated Trial Portfolio for Bexmarilimab	PU
13/07	Faron Provides Update on Investigator-Initiated Trial Portfolio for Bexmarilimab	AQ
01/07	Faron Pharmaceuticals Ltd: Grant of Options	AQ
22/06	FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY	AQ
17/06	FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY	AQ
15/06	Faron Pharmaceuticals Ltd: Holding(s) in Company	AQ
15/06	Faron Pharmaceuticals Oy : Presents Matured BEXMAB Data at EHA 2026 Confirming Durable Efficacy and Bone Marrow Reprogramming in HR-MDS	PU
11/06	Faron Pharmaceuticals Ltd: Registration of Treasury Shares	AQ
10/06	Faron Pharmaceuticals Ltd: Holding(s) in Company	AQ
05/06	Faron Pharmaceuticals Receives Decision from Nasdaq Helsinki Disciplinary Committee	AQ
04/06	Faron Pharmaceuticals Ltd: Holding(s) In Company	AQ
28/05	Faron Pharmaceuticals LTD: Holding(S) In Company	AQ
28/05	Faron Pharmaceuticals Ltd: Special Rights attached to the First and Second Tranche of Bonds	AQ
18/05	Faron Pharmaceuticals LTD: Holding(s) In Company	AQ
15/05	Faron Pharmaceuticals Oy : AGM Minutes (Faron Pharmaceuticals Minutes AGM 202616946421.2)	PU
13/05	Faron to Present New BEXMAB Translational and Clinical Data in HR-MDS at EHA 2026	AQ
06/05	Faron Pharmaceuticals Ltd: Termination of Liquidity Provision Service	AQ
05/05	Faron Pharmaceuticals Ltd: Holding(S) In Company	AQ